BioClinica, Inc. is a specialized provider of clinical trial services to the world’s largest pharmaceutical and biotechnology companies. Water Street facilitated a merger between BioClinica and CCBR-SYNARC in 2014 to create the world’s foremost medical imaging and cardiovascular core lab. The combined company offers the industry’s most comprehensive clinical imaging platform across all major therapeutic areas. In addition, it can support customers with two of their biggest pain points – recruiting large patient populations from diverse geographies to enroll in clinical trials and maximizing the efficiency of the entire drug development process. BioClinica offers cardiovascular safety and efficacy services that measure the effects of compounds under development on cardiac health, as well as central lab capabilities that analyze biological samples originating from trials.
President & CEOWork with us
Mark Weinstein has served as president and chief executive officer of BioClinica since 1998. Previously, he was chief operating officer of Internet Tradeline, Inc., an internet-based electronic solutions provider. Mark also worked for Medical Economics Company, an international healthcare information company and wholly-owned division of The Thomson Corporation. He held several senior management positions at Medical Economics Company, serving as president and chief operating officer of the International Group. Mark received his bachelor’s degree in economics from the University of Virginia and his master’s in business administration from the College of William and Mary.